Introduction
Although percutaneous coronary intervention is currently widely accepted as a treatment of coronary artery disease, restenosis rate is still relatively high. Pathological analysis of human coronary arterial restenotic neointima after stenting showed that extracellular matrix (ECM) accumulation plays an important role in neointima formation (Strauss et al., 1992; Chung et al., 2002) . Transforming growth factor β1 (TGF-β1) is known as a multifunctional cytokine that regulates cell proliferation and differentiation, angiogenesis, and synthesis of a variety of ECM components such as proteoglycans, hyaluronan, fibronectin, and collagen (Schönherr et al., 1991; Chen et al., 1993; Nabel et al., 1993; Schönherr et al., 1993; Dijike et al., 1994; Yamamoto et al., 1996; Schulick et al., 1998; McCaffrey et al., 2000) . And its expression was significantly higher in restenotic lesions compared with primary lesions (Nikol et al., 1992) . Blocking TGF-β1 activity with neutralizing antibody fol-lowing vascular injury decreases ECM accumulation and suppressed intimal hyperplasia in the rat model of arterial injury (Wolf et al., 1994) . Most cells have three types of TGF-β receptors (type I, type II, and type III) at the cell surface, and both type I and type II receptor are necessary for all tested biological activity of TGF-β, whereas type III is not known to mediate any of the known biological activity of TGF-β (Chen et al., 1993; Dijike et al., 1994) . Type II receptor is a member of the transmembrane receptor serine-threonine kinase family, and TGF-β signals through a heteromeric complex between the type I and type II receptors (Chen et al., 1993; Bassing et al., 1994; Dijike et al., 1994) . Binding of TGF-β to the type I receptor requires the presence of the type II receptor, whereas type II receptor binds TGF-β independently (Bassing et al., 1994; Dijike et al., 1994) . Type I receptor requires the presence of a functional type II TGF-β receptor to signal, and trans-phosphorylation of the type I receptor by the type II receptor seems to be essential for signaling (Bassing et al., 1994; Yamamoto et al., 1996) .
As a consequence of developments in the field of molecular biology, strategies targeting TGF-β has been recently developed. For example, ribozyme oligonucleotides cleave the mRNA of TGF-β, leading to decreased expression (Yamamoto et al., 2000) . An adenoviral vector expressing the ectodomain of the type II TGF-β receptor (AdTβ-ExR) inhibits the action of TGF-β both in vitro and in vivo (Smith et al., 1999; Sakamoto et al., 2000) . This soluble receptor is also known to be able to reach remote areas by means of systemic circulation. Recent animal trials using either ribozyme oligonucleotides or soluble type II TGF-β receptor to inhibit TGF-β in vascular injury model showed beneficial effects by inhibiting either neointima or negative vascular remodeling (Smith et al., 1999; Yamamoto et al., 2000; Kingston et al., 2001) . These studies used different gene transfer methods including systemic intravenous injection (Smith et al., 1999) , retention of agents in surgically isolated vascular segment (Yamamoto et al., 2000) , or Infilt-rator (Kingston et al., 2001) . Local delivery of agent without any significant systemic untoward effect would be preferred to systemic injection for gene therapy in the local vascular lesion. Gene transfection using channeledballoon angioplasty catheter which allows low pressure local agent delivery through perforated channels has low efficiency in gene delivery (Feldman et al., 1996) . Thus it is conceivable that gene transfection by transient retention of adenovirus in the isolated vascular segment probably has very low gene transfection efficiency. The Infiltrator is a balloon catheter with 21 injector ports in three lines designed for direct intramural injection of the desired agent. Previous studies using an Infiltrator, in general, agree that it is an effective tool for intravascular drug or gene delivery, but knowledge about efficacy of gene expression at different titer of virus vector and about procedural complication is limited.
Since local blockade of TGF-β seems to have therapeutic potential in the vascular pathology, we carried out catheter-based adenovirus mediated local intravascular delivery of a soluble TGF-β type II receptor using an Infiltrator in a porcine coronary arterial model to know about the expression pattern of this transgene, inflammatory reaction, feasibility and complications of catheter-based gene therapy. And we also tried to identify the minimum titer of virus vector with which the soluble receptor can be expressed in the selected arterial segment without any significant dissemination into remote areas.
Materials and Methods

Recombinant adenovirus vectors
Replication-defective E1-and E3-recombinant adenovirus expressing either an entire ectodomain of the TGF-β type II receptor fused to the human immunoglobulin Fc portion (AdTβ-ExR) or β-galactosidase (AdCALacZ) under a CA promoter, composed of cytomegalovirus enhancer and chicken β-actin promoter, was constructed as described previously (Ueno et al., 1995; Qi et al., 1999) . TGF-β type II soluble receptor is known to be secreted from AdTβ-ExR-infected cells, binds to TGF-β and inhibits TGF-β signaling (Sakamoto et al., 2000) . Both AdTβ-ExR and AdCALacZ were used as adenoviral vectors for gene delivery in porcine coronary arteries. The titer of virus was quantified by a plaque formation assay using 293 cells and expressed as plaque formation units (pfu).
Local gene delivery at porcine coronary artery
Thirteen domestic female pigs (2-3 month old, weighing 25-30 kg) underwent coronary artery intravascular gene delivery using an Infiltrator (Interventional Technologies, San Diego, CA). All animal care and handling were performed in accordance with the guideline specified by the National Institute of Health Guide for the Care and Use of Laboratory animals and were approved by the Animal Care and Use Committee of Yonsei University. Animals took 100 mg of aspirin and 75 mg of clopidogrel 24 h before procedure and continued to take these medication until sacrifice. Before anesthesia, pigs subjected intramuscular injection of atropine (0.04 mg/ kg) and rompun (2 mg/kg). After endotracheal intubation, anesthesia was induced by inhalation of 2.5% enflurane. Heparin (3,000 IU) was injected intravenously before coronary arterial intervention. An 8 F Judkins right coronary artery guide catheter was inserted through the left carotid artery. Coronary arterial segments in the left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA) feasible for intravascular gene delivery using an Infiltrator (3.0-3.5 mm) were selected. An infiltrator was used for injection of 400 µl of each adenoviral vector following inflation of the Infiltrator to 2 atmosphere. Coronary angiogram was performed at both before and immediately after gene delivery. Intracoronary injection of isosorbide dinitrate (200 µg) was performed before angiogram to relieve any possible vasospasm. To identify optimal titer of adenoviral vector for effective gene transfer, three different titers of AdTβ-ExR (1 x 10 8 , 5 x 10 8 , or 1 x 10 9 pfu in 400 µl PBS) and two different titers of AdCALacZ (2.5 x 10 7 or 2.5 x 10 8 pfu in 400 µl PBS) were randomly injected into each coronary arterial segment in three pigs (No. 1-3 in Table 1 ). The rest of pigs undertook intravascular injection of adenoviral vector or PBS as shown in Table 1 . After gene delivery, catheters were removed, and left carotid artery was ligated.
To identify the efficiency of gene transfer, three pigs (No. 1-3 in Table 1 ) were sacrificed at 1 week after gene delivery. Three pigs (No. 4, 7, 12 in Table 1 ) died during the procedure due to complications, and seven pigs were sacrificed at 4 weeks after gene delivery. Coronary arterial segments from each adenovirus injected site were retrieved. Thoracic aorta as well as remote coronary arterial segments were used as negative control tissues. Coronary arteries dissected at 1 week after gene delivery were snap-frozen in liquid nitrogen, and were divided into two pieces: one embedded in OCT for cryostat sectioning and the other kept in 70 o C until RNA assay. Arterial specimens dissected from the rest of pigs were pressure-fixed in situ with 4% formaldehyde, and embedded in paraffin.
Histochemical analysis for β β β β-galactosidase
Pigs were sacrificed 1 week after gene delivery with a lethal dose of sodium pentobarbital. Coronary arterial segments were excised, fixed in PBS containing 2% formaldehyde and 0.2% glutaraldehyde for 2 h at 4 o C, embedded in OCT compound, and subjected to cryostat section at 20 µm thickness. Expression of β-galactosidase was evaluated by incubation at 37 o C with the substrate 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal; Sigma, St. Louis, 
Reverse transcription PCR (RT-PCR)
Total cellular RNA from each arterial segments was isolated using RNeasy mini kit (Qiagen, Germany). For reverse transcription and PCR reactions, a PerkinElmer/Cetus DNA thermal cycler (Foster city, CA) was used. Two microgram of total RNA was reverse transcribed in a 25 µl reaction containing 5 µl reverse transcriptase buffer, 25 mM dNTPs, random hexamers (0 
Immunostaining
Identification of soluble TGF-β type II receptor was assessed by using direct immunofluorescent staining to detect human IgG fused to this soluble receptor with fluorescein isothiocyanate (FITC)-conjugated rabbit antihuman IgG (Dako, Carpinteria, CA). Briefly, frozen sections were dried, placed in PBS for 10 min, incubated with FITC-conjugated rabbit anti-human IgG at room temperature for 1 h, rinsed with PBS for 10 min, and mounted with glass coverslip. The immunostained slides with FITC conjugated anti-human IgG complex were assessed by using immunofluorescent microscope, and photographed immediately. T cells were identified in specimens taken at both 1 week and 4 weeks after gene delivery by immunohistochemical staining with rabbit polyclonal anti-human CD3 antibodies (Dako). successful local gene delivery of human TGF-β type II receptor was carried out using an Infiltrator without any significant dissemination of adenovirus vector. RT-PCR products of 28S RNA from each artery showed a band of equal density, which verify a quantitative analysis of human TGF-β type II receptor gene product.
Results
Identification
Identification of soluble receptor
Direct immunofluorescent staining with use of FITCconjugated rabbit anti-human IgG identified the soluble TGF-β type II receptor, and, as shown in Figure 2 , coronary artery injected with 5 x 10 8 pfu AdTβ-ExR showed multiple dispersed immunofluorescent positive soluble receptor-antibody complex particles in around media and adventitia. The soluble TGF-β receptor was more widely dispersed comparing with the distribution of β-galactosidase. On the other hand, remote arteries including remote coronary artery and thoracic aorta showed no discernable immunofluorescent positive particles. Thus, it is conceivable that the soluble receptor delivered by certain range of adenoviral vector could be expressed locally at the site of gene delivery without any significant spread to remote sites.
Identification of β β β β-galactosidase
Gene transfection was also studied by immunohistochemical assay of β-galactosidase in the arteries injected with two different titers of AdCALacZ (2.5 x 10 7 pfu and 2.5 x 10 8 pfu). As shown in Figure 3 , the expression of β-galactosidase was noted locally in around outer media and adventitia at the arterial segment injected with AdCALacZ of 2.5 x 10 8 pfu, and there was no significant spread of β-galactosidase at remote arterial segments. Coronary arterial segments injected with 2.5 x 10 7 pfu AdCALacZ had no expression of β-galactosidase (data not shown).
Inflammation
CD3
+ T cells were infiltrated around adventitia and, with less extent, media in arteries 1 week after injection with either AdCALacZ or AdTβ-ExR (Figure 4 ). More T cells were infiltrated in segments injected with AdCALacZ comparing to that with AdTβ-ExR. The numbers of infiltrated T cells tend to decrease over time after gene delivery, and there were only a few T cells present in arteries 4 weeks after injection of adenovirus vector (data not shown). The remote coronary artery has no CD3 + T cells as shown in Figure 4 .
Procedural complications
As shown in Table 1 , ten pigs survived after catheter- based gene delivery. Total three pigs died during the procedure. Two pigs died due to ventricular tachycardia induced by intimal dissection and subsequent total occlusion of the artery. Pathological study of these arteries revealed disruption of either external elastic lamina or, less frequently, of tunica media with hemorrhage in ruptured space (Figure 5B and 5C) . Minimal dissection at the external elastic lamina without any significant compromise of coronary circulation was noted in one artery. In addition, interruption of the endothelial layer and internal elastic lamina, miniscule channel penetrating into media with protrusion of nest of cells in a loose ECM, medial thickening caused by edema, and interrupted medial layer were also noted ( Figure 5A ). One pig died due to the failure of deballooning of the Infiltrator and subsequent intravascular occlusive thrombosis. Transient coronary arterial spasm responding to intracoronary nitrate injection occurred in three arterial segments. Ventricular tachycardia associated with arterial spasm were often fatal in our study: only one of four pigs with ventricular tachycardia survived after direct current cardioversion.
Discussion
We studied the efficacy and complications of adenovirus mediated local intravascular delivery of a soluble TGF-β type II receptor using an Infiltrator in a porcine coronary arterial model known to be very similar to that of human (Muller et al., 1992) . Expression of β-galactosidase delivered by an Infiltrator was mostly localized around outer media and adventitia, which seems to be related with the height (279 µm) of injector ports. And similar observations were reported by other studies (Morishige et al., 2000; Kingston et al., 2001 ). Our study suggested that no significant dissemination of adenovirus occurred, since transgene, ectodomain of human TGF β type II receptor mRNA, was localized in the injection segment. And this finding is consistent with the previous study (Feldman et al., 1995) . The soluble TGF-β receptor delivered by injection of 5 x 10 8 pfu AdTβ-ExR was more widely dispersed in around media and adventitia comparing with that of β-galactosidase, but neither TGF-β receptor nor β-galactosidase was found at remote arterial segments. The same soluble receptor is capable to reach remote areas by means of systemic circulation in other study. Intramuscular injection of same amount of AdTβ-ExR (5 x 10 8 pfu) in a mouse showed that an increase of concentration of this soluble receptor was noted not only in the serum, but also in the remote organ (Sakamoto et al., 2000) . This discrepancy is probably caused by the difference of dilution of soluble TGF-β receptor between two different animal models. Our animal model (pig, ≅30 kg) which is much larger than that of the other study (mouse, ≅30 g) should enable the soluble receptor to dilute significantly in the systemic circulation.
A replication-defective adenoviral vector has several advantages over other vectors for in vivo gene transfer to intravascular model. The adenovirus vectors, unlike the retroviruses, are effective in delivering gene in nondividing vascular cells (Wivel et al., 1998) . Vascular cellular replication rate is known to be very low (mostly 0-1%) in human arterial tissue, which is true in human restenotic arterial tissue as well as in primary atherosclerotic plaque (Gordon et al., 1990; OBrien et al., 1993; Chung et al., 2002) . Cell replication rate is also known to be low (≤ 5%) in injured rabbit artery (Strauss et al., 1994) and in our porcine coronary stent neointima specimens (unpublished data). In addition, adenoviral vectors are stable in the blood stream, and adenoviral DNA is not integrated into the host cell chromosome.
An adenoviral vector expressing the ectodomain of the type II TGF-β receptor (AdTβ-ExR) inhibits the action of TGF-β by adsorbing TGF-β, but it may act as a dominant negative receptor (Sakamoto et al., 2000) . As a possible mechanism of dominant negative mutation, Chen et al. suggested that truncated and wild type receptor form heterodimers and abrogate further sig-naling via either accelerated degradation of the hetero-dimers or impaired transport of the wild type receptor to the cell surface that accounts for reduced level of endogenous type II receptor. In addition, truncated type II receptor may form a heterodimer with type I receptor preventing an interaction of the endogenous type II receptor and type I receptor. Therefore, it is noteworthy that due to the intrinsic competitive nature of dominant negative mutants the expression level of soluble receptor needs to greatly exceed that of the endogenous receptor (Chen et al., 1993) .
Host immune response and dose-dependent inflammatory and cytopathic effects inhibit adenoviral gene expression, and impose limitations in gene delivery (Grub et al., 1994; Feldman et al., 1995; Wivel et al. 1998) . Therefore identification of viral titer that is effective in gene expression with minimal inflammatory reaction seems to be important. Gene transfer assay with different titers of each adenoviral vector showed that the minimum adenoviral titers for effective gene expressions were 5 x 10 8 pfu for AdTβ-ExR and 2.5 x 10 8 pfu for AdCALacZ in our study. And arterial segments 1 week after adenoviral vector mediated gene delivery showed CD3 + T cells infiltrated in the area of adventitia and media, and the numbers of infiltrated T cells tend to decrease over time. This is consistent with other study that intramuscular injection of E1 deleted adenoviral vector expressing β-galactosidase in a mice induced a significant inflammatory response characterized by mononuclear cell infiltration and degeneration of muscle fiber (Yang et al., 1996) . This study also showed that inflammation, peaked at 17 days after gene transfer, slowly diminished to baseline over several months, and that the expression of transgene diminished to undetectable level within 30 days. Cellular immunity dependent on CD4 + and CD8 + T cells limit the duration of vector derived transgene expression, and humoral immunity also plays a role in diminishing gene transfer following a second administration of vector (Yang et al., 1994; Yang et al., 1995; Yang et al., 1996) . Activation of CD8 + T cells is known to be induced by viral capsid proteins, newly expressed viral proteins, and the transgene product (Yang et al., 1996) . In our study, infiltrated CD3 positive T cells were more in segments injected with AdCALacZ comparing to that with AdTβ-ExR. This finding is consistent with other study (Kingston et al., 2001) , and should be considered in the context with the concept that β-galactosidase has the potential for eliciting immune responses (Danko et al., 1994; Yang et al., 1996) .
The Infiltrator was developed as a tool for local intravascular delivery of drug, and has been used in animals Varenne et al., 1998; Morishige et al., 2000; Kingston et al., 2001 ) and rarely in human (Pavlides et al., 1997) . Our study showed that catheter-based local in vivo adenovirus mediated gene transfer using an Infiltrator is, in general, effective and feasible in an arterial segment characterized by diameter of at least 2.5 mm, light tortuosity, minimal angulation (< 45 o ), and free of side branch. However procedurerelated complications such as medial dissection with hemorrhage and subsequent vasospasm occurred in 4 arteries among 24 treated arteries in our study. We occasionally observed that some injector ports of Infiltrator were obliterated after use, which may be a possible cause for the hydraulic dissection due to excess of fluid accumulation at the limited vascular space. Therefore further studies aimed for the improvement of feasibility and safety are necessary before the appli-cation in human.
